About
The Long-Acting Technologies Community Advisory Board is a new cross-disease long-acting technologies (LAT) community advisory board (CAB) focused on malaria, the hepatitis C virus (HCV), HIV, and latent TB infection (LTBI).
The LAT CAB reviews the state of treatment research, contributes to research protocols including those related to product acceptability, and engages in the research and development (R&D) process, including advising on research questions and trial design for long-acting technologies for malaria, HCV, HIV, and LTBI.
Meet the LAT CAB community experts.